In our Case of the Week, the Federal Circuit upheld a Patent Trial and Appeal Board decision invalidating claims on Merck’s multiple sclerosis drug Mavenclad®, an oral formulation of the compound ...
On October 30, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed two inter partes review decisions of the Patent Trial and Appeal Board (“PTAB”) invalidating claims in two of Merck ...
Merck Serono, a division of Merck, Darmstadt, Germany, and Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, today announced a new, ...
DARMSTADT, Germany--(BUSINESS WIRE)--Merck’s Consumer Health division has significantly increased in size following its incorporation of Neurobion ®, a leading global brand in the vitamin B segment, ...
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, ...
DARMSTADT, Germany and PARIS — President and CEO of Merck Serono, Belén Garijo, has been appointed an independent director of L'Oréal. Garijo was appointed to the four-year term during L’Oréal’s 2014 ...
Two more drugmakers have announced they will be restricting some sales of 340B-discounted products to contract pharmacies just two days after the pharma industry was handed a win on the contentious ...
EMD Serono, the American drug development arm of Germany’s Merck KGaA, plans to move its headquarters from the South Shore town of Rockland to Boston’s Seaport district next summer. The company will ...
Jan 15 (Reuters) - ZymoGenetics Inc said its partner Merck Serono, German drugmaker Merck KGaA's affiliate, received approval from U.S. health regulators for the design of a late-stage lupus trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results